This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1916)
- Annex to CHMP highlights(367)
- Annual Report(94)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1980)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2710)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(141)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Overview(1976)
- EPAR - Paediatric investigation plan compliance statement(89)
- EPAR - Procedural steps taken and scientific information after authorisation(1887)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1976)
- EPAR - Public assessment report(1551)
- EPAR - Risk-management-plan summary(1143)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(72)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(24)
- Minutes(1250)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4061)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2763)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5490)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5308)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2778)
- Regulatory and procedural guideline(723)
- Report(1620)
- Scientific guideline(2465)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1223)
- Summary of opinion - Initial authorisation(1675)
- Supply shortage(58)
- Template or form(480)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- (-)EPAR - Conditions imposed on member states for safe and effective use(112)
- (-)Maximum Residue Limits - Report(804)
- Advanced therapies(0)
- Antimicrobial resistance(0)
- Biologicals(0)
- Biosimilars(3)
- Brexit(0)
- Careers(0)
- Clinical trials(0)
- Compassionate use(0)
- Compliance and inspections(0)
- Corporate(0)
- COVID-19(0)
- Data on medicines(0)
- Early access(0)
- Fees(0)
- Generic and hybrid medicines(17)
- Governance(0)
- Innovation(0)
- Maximum residue limit(804)
- Medication error(0)
- Medicines(911)
- Medicines for use outside the EU(0)
- Medicine shortages(0)
- Mpox(0)
- Paediatrics(1)
- Parallel distribution(0)
- Pharmacovigilance(0)
- Procurement(0)
- Product information(22)
- Quality of medicines(0)
- Rare diseases(0)
- Referrals(0)
- Regulatory and procedural guidance(0)
- Research and development(0)
- Scientific advice(0)
- Scientific guidelines(0)
- SME(0)
- Vaccines(0)
- Veterinary limited markets(0)
Search results (916)
Sodium salicylate (poultry other than turkey): European Public MRL Assessment Report (EPMAR) - CVMP
English (EN) (275.49 KB - PDF)
Ketoprofen : call for scientific data for use in CVMP assessment work of ketoprofen: review of the CVMP opinion for the establishment of maximum residue limits
English (EN) (147.59 KB - PDF)
Pomalidomide Viatris : EPAR - Conditions imposed on member states for safe and effective use - Annex related to Art. 127a
English (EN) (262.16 KB - PDF)
български (BG) (228.13 KB - PDF)
español (ES) (119.61 KB - PDF)
čeština (CS) (216.31 KB - PDF)
dansk (DA) (132.77 KB - PDF)
Deutsch (DE) (171.55 KB - PDF)
eesti keel (ET) (183.4 KB - PDF)
ελληνικά (EL) (184.48 KB - PDF)
français (FR) (220.72 KB - PDF)
hrvatski (HR) (216.38 KB - PDF)
íslenska (IS) (161.79 KB - PDF)
italiano (IT) (192 KB - PDF)
latviešu valoda (LV) (180.13 KB - PDF)
lietuvių kalba (LT) (203.91 KB - PDF)
magyar (HU) (217.53 KB - PDF)
Malti (MT) (172.14 KB - PDF)
Nederlands (NL) (149.61 KB - PDF)
norsk (NO) (66.01 KB - PDF)
polski (PL) (220.79 KB - PDF)
português (PT) (127.61 KB - PDF)
română (RO) (186.51 KB - PDF)
slovenčina (SK) (206.51 KB - PDF)
slovenščina (SL) (176.31 KB - PDF)
Suomi (FI) (141.11 KB - PDF)
svenska (SV) (168.81 KB - PDF)
Thalidomide BMS (previously Thalidomide Celgene) : EPAR - Conditions imposed on member states for safe and effective use - Annex IV
English (EN) (20.77 KB - PDF)
български (BG) (81.47 KB - PDF)
español (ES) (21.78 KB - PDF)
čeština (CS) (82.26 KB - PDF)
dansk (DA) (21.17 KB - PDF)
Deutsch (DE) (21.12 KB - PDF)
eesti keel (ET) (21.35 KB - PDF)
ελληνικά (EL) (90.67 KB - PDF)
français (FR) (21.69 KB - PDF)
hrvatski (HR) (77.98 KB - PDF)
íslenska (IS) (21.4 KB - PDF)
Gaeilge (GA) (21.77 KB - PDF)
italiano (IT) (22.24 KB - PDF)
latviešu valoda (LV) (84.23 KB - PDF)
lietuvių kalba (LT) (80.41 KB - PDF)
magyar (HU) (78.73 KB - PDF)
Malti (MT) (87.35 KB - PDF)
Nederlands (NL) (21.6 KB - PDF)
norsk (NO) (20.82 KB - PDF)
polski (PL) (83.12 KB - PDF)
português (PT) (18.68 KB - PDF)
română (RO) (80.04 KB - PDF)
slovenčina (SK) (86.47 KB - PDF)
slovenščina (SL) (79.97 KB - PDF)
Suomi (FI) (24.46 KB - PDF)
svenska (SV) (18.52 KB - PDF)
Azamethiphos (extension to fin fish): European public maximum-residue-limit assessment report (EPMAR)
On 23 May 2012 the European Commission adopted a Regulation1 establishing maximum residue limits for azamethiphos in fin fish, valid throughout the European Union. These maximum residue limits were based on the favourable opinion and the assessment report adopted by the Committee for Medicinal Products for Veterinary Use.
English (EN) (258 KB - PDF)
Praziquantel (fin fish): European public MRL assessment report (EPMAR) - CVMP
English (EN) (265.9 KB - PDF)
Revlimid : EPAR - Conditions imposed on member states for safe and effective use - Annex IV
English (EN) (16.71 KB - PDF)
български (BG) (117.69 KB - PDF)
español (ES) (18.65 KB - PDF)
čeština (CS) (78.1 KB - PDF)
dansk (DA) (18.84 KB - PDF)
Deutsch (DE) (131.31 KB - PDF)
eesti keel (ET) (17.59 KB - PDF)
ελληνικά (EL) (89.44 KB - PDF)
français (FR) (17.69 KB - PDF)
hrvatski (HR) (74.27 KB - PDF)
íslenska (IS) (18.19 KB - PDF)
Gaeilge (GA) (20.79 KB - PDF)
italiano (IT) (18.35 KB - PDF)
latviešu valoda (LV) (76.1 KB - PDF)
lietuvių kalba (LT) (78.08 KB - PDF)
magyar (HU) (76.73 KB - PDF)
Malti (MT) (82.54 KB - PDF)
Nederlands (NL) (19.95 KB - PDF)
norsk (NO) (17.85 KB - PDF)
polski (PL) (81.23 KB - PDF)
português (PT) (17.79 KB - PDF)
română (RO) (78.52 KB - PDF)
slovenčina (SK) (79.84 KB - PDF)
slovenščina (SL) (78.2 KB - PDF)
Suomi (FI) (17.36 KB - PDF)
svenska (SV) (18.31 KB - PDF)
Imnovid : EPAR - Conditions imposed on member states for safe and effective use - Annex related to the Art. 127a
English (EN) (23.19 KB - PDF)
български (BG) (81.48 KB - PDF)
español (ES) (24.09 KB - PDF)
čeština (CS) (83.03 KB - PDF)
dansk (DA) (23.48 KB - PDF)
Deutsch (DE) (35.11 KB - PDF)
eesti keel (ET) (23.54 KB - PDF)
ελληνικά (EL) (107.17 KB - PDF)
français (FR) (23.14 KB - PDF)
hrvatski (HR) (78.16 KB - PDF)
íslenska (IS) (24.06 KB - PDF)
Gaeilge (GA) (21.83 KB - PDF)
italiano (IT) (24.18 KB - PDF)
latviešu valoda (LV) (82.53 KB - PDF)
lietuvių kalba (LT) (82.47 KB - PDF)
magyar (HU) (80 KB - PDF)
Malti (MT) (90.32 KB - PDF)
Nederlands (NL) (24.21 KB - PDF)
norsk (NO) (23.36 KB - PDF)
polski (PL) (84.65 KB - PDF)
português (PT) (24.15 KB - PDF)
română (RO) (83.38 KB - PDF)
slovenčina (SK) (112.08 KB - PDF)
slovenščina (SL) (79.12 KB - PDF)
Suomi (FI) (23.08 KB - PDF)
svenska (SV) (25.02 KB - PDF)
Imnovid : EPAR - Conditions imposed on member states for safe and effective use
English (EN) (23.19 KB - PDF)
български (BG) (81.48 KB - PDF)
español (ES) (24.09 KB - PDF)
čeština (CS) (83.03 KB - PDF)
dansk (DA) (23.48 KB - PDF)
Deutsch (DE) (35.11 KB - PDF)
eesti keel (ET) (23.54 KB - PDF)
ελληνικά (EL) (107.17 KB - PDF)
français (FR) (23.14 KB - PDF)
hrvatski (HR) (78.16 KB - PDF)
íslenska (IS) (24.06 KB - PDF)
Gaeilge (GA) (21.83 KB - PDF)
italiano (IT) (24.18 KB - PDF)
latviešu valoda (LV) (82.53 KB - PDF)
lietuvių kalba (LT) (82.47 KB - PDF)
magyar (HU) (80 KB - PDF)
Malti (MT) (90.32 KB - PDF)
Nederlands (NL) (24.21 KB - PDF)
norsk (NO) (23.36 KB - PDF)
polski (PL) (84.65 KB - PDF)
português (PT) (24.15 KB - PDF)
română (RO) (83.38 KB - PDF)
slovenčina (SK) (112.08 KB - PDF)
slovenščina (SL) (79.12 KB - PDF)
Suomi (FI) (23.08 KB - PDF)
svenska (SV) (25.02 KB - PDF)
Lenalidomide Krka d.d. : EPAR - Conditions imposed on member states for safe and effective use
English (EN) (141.96 KB - PDF)
български (BG) (271.46 KB - PDF)
español (ES) (170.99 KB - PDF)
čeština (CS) (237.64 KB - PDF)
dansk (DA) (165.41 KB - PDF)
Deutsch (DE) (167.56 KB - PDF)
eesti keel (ET) (151.86 KB - PDF)
ελληνικά (EL) (272.7 KB - PDF)
français (FR) (164.22 KB - PDF)
hrvatski (HR) (201.27 KB - PDF)
íslenska (IS) (176.31 KB - PDF)
italiano (IT) (206.38 KB - PDF)
latviešu valoda (LV) (221.59 KB - PDF)
lietuvių kalba (LT) (217.51 KB - PDF)
magyar (HU) (192.63 KB - PDF)
Malti (MT) (242.2 KB - PDF)
Nederlands (NL) (169.92 KB - PDF)
norsk (NO) (154.48 KB - PDF)
polski (PL) (217.89 KB - PDF)
português (PT) (168.82 KB - PDF)
română (RO) (281.4 KB - PDF)
slovenčina (SK) (206.02 KB - PDF)
slovenščina (SL) (191.03 KB - PDF)
Suomi (FI) (156.36 KB - PDF)
svenska (SV) (164.79 KB - PDF)